Metlife Inc (MET) concluded trading on Wednesday at a closing price of $82.82, with 4.07 million shares of worth about $337.18 million changed hands on the day. Half year performance of the stock remained positive as price took a surge of 15.64% during that period and on January 08, 2025 the price saw a gain of about 0.83%. Currently the company’s common shares owned by public are about 693.65M shares, out of which, 578.50M shares are available for trading.
Stock saw a price change of 1.15% in past 5 days and over the past one month there was a price change of -2.82%. Year-to-date (YTD), MET shares are showing a performance of 1.15% which increased to 19.13% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $64.61 but also hit the highest price of $89.05 during that period. The average intraday trading volume for Metlife Inc shares is 3.20 million. The stock is currently trading 1.26% above its 20-day simple moving average (SMA20), while that difference is up 0.05% for SMA50 and it goes to 8.19% higher than SMA200.
Metlife Inc (NYSE: MET) currently have 693.65M outstanding shares and institutions hold larger chunk of about 75.17% of that.
The stock has a current market capitalization of $57.35B and its 3Y-monthly beta is at 1.06. PE ratio of stock for trailing 12 months is 16.70, while it has posted earnings per share of $4.96 in the same period. Its PEG reads 1.19 while making debt-to-equity ratio of 0.63. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for MET, volatility over the week remained 2.06% while standing at 2.12% over the month.
Stock’s fiscal year EPS is expected to rise by 13.09% while it is estimated to increase by 17.45% in next year. EPS is likely to grow at an annualized rate of 14.03% for next 5-years, compared to annual growth of -18.10% made by the stock over the past 5-years.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by TD Cowen on October 09, 2024 offering a Buy rating for the stock and assigned a target price of $97 to it. Coverage by Barclays stated Metlife Inc (MET) stock as an Overweight in their note to investors on September 05, 2024, suggesting a price target of $91 for the stock. On January 08, 2024, Goldman Upgrade their recommendations, while on November 17, 2023, Barclays Resumed their ratings for the stock with a price target of $71. Stock get a Hold rating from Deutsche Bank on October 05, 2023.
